BiotechTube
Moligo Technologies

Moligo Technologies

Stockholm, Sweden· Est.
moligotechnologies.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.1M

Overview

Moligo Technologies is a private, Stockholm-based biotech providing high-purity, long single-stranded DNA (ssDNA) as a critical reagent for next-generation genetic medicine and research. The company's core innovation is a patented Enzymatic Injection Molding technology that overcomes the length, purity, and scalability limitations of traditional chemical DNA synthesis and fermentation methods. Moligo operates primarily as a platform and service provider, supplying custom ssDNA to partners in gene therapy and CRISPR while also engaging in co-development programs. Backed by family offices and specialist healthcare investors, the company is positioned to enable a new class of DNA-based tools and therapies.

Genetic Diseases

Technology Platform

Proprietary Enzymatic Injection Molding (EIM) technology for synthesizing ultrapure, long (up to 10 Kb), single-stranded DNA (ssDNA) at industrial scale (gram batches) with >99.9999% fidelity.

Funding History

2
Total raised:$3.1M
Grant$600K
Seed$2.5M

Opportunities

The rapid growth of cell/gene therapy and CRISPR markets creates massive demand for high-quality DNA starting materials.
Moligo's ultrapure, long ssDNA is positioned as a superior alternative to plasmid DNA, potentially improving therapy safety and manufacturing scalability.
The platform also enables expansion into non-therapeutic fields like agriculture, diagnostics, and biomaterials.

Risk Factors

Faces intense competition from established DNA synthesis companies and new enzymatic synthesis startups.
Success is dependent on adoption by therapeutic developers, who may stick with plasmid DNA standards.
Scaling its proprietary enzymatic process to consistent, cost-effective industrial production presents significant technical and operational risks.

Competitive Landscape

Moligo competes in the DNA synthesis market against large players like Twist Bioscience and IDT (using phosphoramidite chemistry) and a new generation of enzymatic synthesis companies like DNA Script and Ansa Biotechnologies. Its key differentiators are the combination of very long length (10 Kb), ultra-high purity, and claimed industrial scalability for single-stranded DNA, a niche not fully addressed by competitors.

More companies in Synthetic Biology →More companies in Sweden →